On June 7, 2018 ArQule, Inc. (Nasdaq: ARQL) reported clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA (Free EHA Whitepaper) Congress in Stockholm, Sweden (Press release, ArQule, JUN 7, 2018, View Source [SID1234527220]). ARQ 531 is an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Friday, June 15, 2018: Chronic lymphocytic leukemia and related disorders – Clinical
Title: A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies
Location: Poster area
Time:17:30-19:00 CET
Abstract Code: PF355

About BTK and ARQ 531

Bruton’s tyrosine kinase, BTK, is a therapeutic target that has been clinically proven to inhibit B-cell receptor signaling in blood cancers. ARQ 531 is an orally bioavailable, potent and reversible BTK inhibitor. Biochemical and cellular studies have shown that ARQ 531 inhibits both the wild type and C481S-mutant forms of BTK. The C481S mutation is a known resistance mechanism for first generation irreversible BTK inhibitors. In preclinical studies, ARQ 531 has demonstrated good oral bioavailability as well as favorable pharmacokinetic, pharmacodynamic and metabolic properties.